1. Arancibia, S., Enjalbert, A., Ruberg, M., Priam, M., Bluet-Pajot, M. T., and Kordon, C., 1981, Activité PRF (prolactin releasing factor) du VIP (vasoactive intestinal peptide) in vitro, J. Physiol. (Paris), 77: 979.
2. Barnes, G. D., Brown, B. L., Gard, T. G., Atkinson, D., and Ekins, R. P., 1978, Effect of TRH and dopamine on cyclic AMP levels in enriched mammotroph and tyrotroph cells, Mol. Cell. Endocr., 12: 275.
3. Bataille, D., Peillon, F., Besson, J., and Rosselin, G., 1979, Vasoactive intestinal peptide (VIP): Récepteurs spécif iques et activation de l’adénylate cyclase dans une tumeur hypophysaire humaine à prolactine, C. R. Acad. Sci. ( Paris ), 288: 1315.
4. Bauer, K., Graf, K. J., Faivre-Bauman, A., Beier, S., TixierVidal, A., and Kleinkauf, M., 1978, Inhibition of prolactin secretion by histidyl-proline-diketopiperazine. Nature, 274: 174.
5. Bicknell, R. J., Young, P. W., Schofield, J. G., and Albano, J., 1977, Mechanism of action of somatostatin: Growth hormone release, [45Ca] calciuth ion efflux and cyclic nucleotides